Minerva Neurosciences (NERV) Total Current Liabilities (2013 - 2026)
Minerva Neurosciences posted quarterly Total Current Liabilities of $4.5 million for Q1 2026, up 130.19% year-on-year from $1.9 million in Q1 2025, and up 95.69% on a QoQ basis from $2.3 million in Q4 2025.
Minerva Neurosciences (NERV) has 14 years of Total Current Liabilities data on file, last reported at $4.5 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities rose 130.19% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $4.5 million (up 130.19% YoY), and the FY2025 full-year result was $2.3 million, down 19.26% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $4.5 million, up from $2.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $4.5 million in Q3 2024 and bottomed at $1.4 million in Q4 2022.
- The 5-year median for Total Current Liabilities is $2.8 million (2024), against an average of $2.9 million.
- The widest annual swing landed in 2022, when Total Current Liabilities sank 51.13%; it then surged 142.49% in 2023.
- A 5-year view of Total Current Liabilities shows it stood at $1.4 million in 2022, then jumped by 142.49% to $3.3 million in 2023, then slipped by 15.08% to $2.8 million in 2024, then dropped by 19.26% to $2.3 million in 2025, then jumped by 95.69% to $4.5 million in 2026.
- The last three Total Current Liabilities figures came in at $4.5 million (Q1 2026), $2.3 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | 4.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.48 Mn |
| Dec 31, 2025 | 2.29 Mn |
| Sep 30, 2025 | 2.67 Mn |
| Jun 30, 2025 | 2.53 Mn |
| Mar 31, 2025 | 1.95 Mn |
| Dec 31, 2024 | 2.84 Mn |
| Sep 30, 2024 | 4.48 Mn |
| Jun 30, 2024 | 4.20 Mn |
| Mar 31, 2024 | 2.83 Mn |
| Dec 31, 2023 | 3.34 Mn |
| Sep 30, 2023 | 3.35 Mn |
| Jun 30, 2023 | 1.91 Mn |
| Mar 31, 2023 | 2.50 Mn |
| Dec 31, 2022 | 1.38 Mn |
| Sep 30, 2022 | 2.20 Mn |
| Jun 30, 2022 | 3.41 Mn |
| Mar 31, 2022 | 3.25 Mn |
| Dec 31, 2021 | 2.82 Mn |
| Sep 30, 2021 | 3.08 Mn |
| Jun 30, 2021 | 4.44 Mn |
| Mar 31, 2021 | 3.36 Mn |
| Dec 31, 2020 | 3.16 Mn |
| Sep 30, 2020 | 5.39 Mn |
| Jun 30, 2020 | 7.40 Mn |
| Mar 31, 2020 | 7.12 Mn |
| Dec 31, 2019 | 6.63 Mn |
| Sep 30, 2019 | 9.90 Mn |
| Jun 30, 2019 | 7.59 Mn |
| Mar 31, 2019 | 6.90 Mn |
| Dec 31, 2018 | 3.61 Mn |
| Sep 30, 2018 | 3.87 Mn |
| Jun 30, 2018 | 5.02 Mn |
| Mar 31, 2018 | 7.91 Mn |
| Dec 31, 2017 | 6.84 Mn |
| Sep 30, 2017 | 8.72 Mn |
| Jun 30, 2017 | 14.59 Mn |
| Mar 31, 2017 | 12.99 Mn |
| Dec 31, 2016 | 9.69 Mn |
| Sep 30, 2016 | 10.10 Mn |
| Jun 30, 2016 | 6.24 Mn |
| Mar 31, 2016 | 6.97 Mn |
| Dec 31, 2015 | 5.32 Mn |
| Sep 30, 2015 | 3.21 Mn |
| Jun 30, 2015 | 3.81 Mn |
| Mar 31, 2015 | 4.43 Mn |
| Dec 31, 2014 | 3.51 Mn |
| Sep 30, 2014 | 3.18 Mn |
| Jun 30, 2014 | 10.05 Mn |
| Dec 31, 2013 | 1.41 Mn |